Guidance on Meetings with
Industry and Investigators on the Research and Development of
Tobacco Products
Revision of a currently approved collection
No
Regular
09/19/2025
Requested
Previously Approved
36 Months From Approved
09/30/2025
20
65
600
1,820
0
0
This ICR is for a guidance intended to
assist tobacco manufacturers, importers, researchers, and
investigators, and their representatives who seek meetings with
staff of FDA’s Center for Tobacco Products (CTP). This guidance
does not pertain to other types of meetings or meeting requests
with CTP staff. The Federal Food, Drug, and Cosmetic Act (FD&C
Act), as amended by the Family Smoking Prevention and Tobacco
Control Act (Tobacco Control Act) offers several pathways to obtain
an order from FDA to authorize the marketing of a new tobacco
product before it may be introduced or delivered into interstate
commerce. To provide assistance with these pathways to market
products, FDA will meet with tobacco product manufacturers,
importers, researchers, and investigators (or their
representatives) where appropriate. This guidance is intended to
assist persons who seek guidance relating to their research to
inform the regulation of tobacco products or to support the
development or marketing of tobacco products. This guidance
describes two collections of information: (1) The submission of a
meeting request containing certain information and (2) the
submission of a meeting information package in advance of the
meeting. The purpose of the meeting information package is to
provide Agency staff the opportunity to adequately prepare for the
meeting, including the review of relevant data concerning the
product. In the Agency’s experience, reviewing such information is
critical to achieving a productive meeting. For information that
was previously submitted in a meeting request, the information
package should provide updated information that reflects the most
current and accurate information available.
PL:
Pub.L. 111 - 111 31 Name of Law: Family Smoking Prevention and
Tobacco Control Act
Based on the combined impacts
of program changes and adjustments describes above, FDA’s estimated
burden for the entire information collection reflects an overall
annual decrease of 1,220 hours and 90 respondents (45 fewer
respondents submitting meeting requests, and 45 fewer respondents
submitting metting information packages). The total burden hours
for the collection have been reduced from 1,820 hours to 600 total
hours. FDA’s estimated cost burden to the respondents has increased
from $53,437.20 to $92,274 due to a re-assessment of staff
occupational employment categories needed to create and review
meeting requests and packages.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.